A Battle Between Two Biological Singularities: Immune Response Vs. Cancer

Overview

Journal Biophys Physicobiol

Specialty Biophysics

Date 2024 Aug 23

PMID 39175864

Authors

Tomoya Katakai

Taku Okazaki

Affiliations

Soon will be listed here.

Abstract

In a post-growth multicellular organism, the phenomenon in which a small number of rare cells can be the starting point for inducing a dramatic change in the entire system is considered a "biological singularity." The immune response and cancer can be regarded as singularity phenomena in mammals, but their nature is fundamentally different. The immune response is considered a "programmed" singularity, whereas cancer is an "unprogrammed" singularity. These two systems perpetually engage in a cycle of attack and defense within the organism. The outcome is depending on the wining system, which determines whether the individual experiences a state resembling light or darkness. However, the overall mechanism of the competition remains unclear and is expected to be elucidated with future innovations in bioimaging technologies. Immune checkpoint blockade therapy is a means by which the two singularity balances can be artificially manipulated; therefore, mechanistic insight is necessary for cancer treatment strategies. Altogether, these findings provide a different perspective crucial for understanding the behavior of dynamic cell populations in multicellular organisms.

References

Billman G . Homeostasis: The Underappreciated and Far Too Often Ignored Central Organizing Principle of Physiology. Front Physiol. 2020; 11:200. PMC: 7076167. DOI: 10.3389/fphys.2020.00200. View

Moon J, Chu H, Pepper M, McSorley S, Jameson S, Kedl R . Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity. 2007; 27(2):203-13. PMC: 2200089. DOI: 10.1016/j.immuni.2007.07.007. View

Smyth M, Godfrey D, Trapani J . A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001; 2(4):293-9. DOI: 10.1038/86297. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Martins F, Sofiya L, Sykiotis G, Lamine F, Maillard M, Fraga M . Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019; 16(9):563-580. DOI: 10.1038/s41571-019-0218-0. View

Chen D, Mellman I . Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330. DOI: 10.1038/nature21349. View

Swann J, Smyth M . Immune surveillance of tumors. J Clin Invest. 2007; 117(5):1137-46. PMC: 1857231. DOI: 10.1172/JCI31405. View

Greaves M, Maley C . Clonal evolution in cancer. Nature. 2012; 481(7381):306-13. PMC: 3367003. DOI: 10.1038/nature10762. View

Nagai T, Chikuma S, Hanaoka K . Detection of singularity in immunity and cancer by novel imaging techniques. Biophys Physicobiol. 2020; 17:98-99. PMC: 7610062. DOI: 10.2142/biophysico.BSJ-2020018. View

10.

Netea M, Schlitzer A, Placek K, Joosten L, Schultze J . Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host's Response to Pathogens. Cell Host Microbe. 2019; 25(1):13-26. DOI: 10.1016/j.chom.2018.12.006. View

11.

Harty J, Badovinac V . Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol. 2008; 8(2):107-19. DOI: 10.1038/nri2251. View

12.

Yates L, Campbell P . Evolution of the cancer genome. Nat Rev Genet. 2012; 13(11):795-806. PMC: 3666082. DOI: 10.1038/nrg3317. View

13.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

14.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

15.

Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L . Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023; 8(1):9. PMC: 9816309. DOI: 10.1038/s41392-022-01270-x. View

16.

Loeb L . Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer. 2011; 11(6):450-7. PMC: 4007007. DOI: 10.1038/nrc3063. View

17.

Negrini S, Gorgoulis V, Halazonetis T . Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010; 11(3):220-8. DOI: 10.1038/nrm2858. View

18.

Raeber M, Zurbuchen Y, Impellizzieri D, Boyman O . The role of cytokines in T-cell memory in health and disease. Immunol Rev. 2018; 283(1):176-193. DOI: 10.1111/imr.12644. View

19.

Jhunjhunwala S, Hammer C, Delamarre L . Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021; 21(5):298-312. DOI: 10.1038/s41568-021-00339-z. View

20.

Kunzli M, Masopust D . CD4 T cell memory. Nat Immunol. 2023; 24(6):903-914. PMC: 10343737. DOI: 10.1038/s41590-023-01510-4. View